Recent efforts have helped reform the global landscape of drug development to incorporate the unique needs of children into research and regulation. However, an area of persistent inadequacy is public policy on funding for pediatric drugs, which varies widely by jurisdiction. Health systems are increasingly faced with the competing pressures of resource scarcity and innovation. In this environment, emphasis on the comparative value of health interventions is prominent in health policy and system stewardship in most developed nations, including Canada.

Health technology assessment frameworks appraise the cost-effectiveness and wider aspects of the value of “technologies” (i.e., drugs, devices, procedures or services) to inform policy decision-making and resource allocation within publicly funded health systems. As health technology assessment processes have become standardized, challenges have surfaced in the evaluation of therapies for children. Most health technology assessment has focused on adult health. Child health receives little attention, in part, because of lower disease prevalence and the challenges associated with including children in clinical research. There is also growing awareness that health technology assessment as currently conducted presents many conceptual and practical problems in its application to child health.

The poor fit of health technology assessment to the realities of childhood disease and development has abetted an erratic approach to assessing public funding for pediatric drugs, and has potentiated a patchwork of coverage across Canada (Table 1). A national, child-focused policy framework for public drug regulation and funding that recognizes regional concerns and values is essential to correct these shortcomings. We analyze the limitations and challenges presented by prevailing health technology assessment frameworks with respect to children, explore their links to existing market and regulatory realities, and consider potential policy solutions.

Current challenges

System limitations

Canadian processes for appraising health technologies do not take into account the unique characteristics of children and the scientific evidence pertaining to drug indications and utilization in this population. Data concerning new drugs being brought to market are first submitted to Health Canada for approval of safety and efficacy to permit sale in Canada. Once approved, provided consideration for public funding is desired, a submission is made to the national-level health technology assessment organization, the Canadian Agency for Drugs and Technologies in Health (CADTH), which “reviews drugs and makes reimbursement recommendations to Canada’s federal, provincial, and territorial public drug plans, with the exception of Quebec, to guide their drug funding decisions.” Some provinces perform a provincial review, often resulting in different coverage across the country (Figure 1).

Evaluation of a novel drug by either national or provincial committees for a pediatric indication is uncommon; typically, funding recommendations are based on adult indications. This is predominately due to the industry-driven submission process: in most cases, drug licensing and funding submissions are made by manufacturers or by contract research organizations on their behalf.

The lack of attention to child health technology assessment is partly a consequence of market dynamics. Children typically represent a small fraction of the potential market for a given drug. These limited markets are further fragmented by unique disease biology and special formulation requirements for children. More complex still, some drugs have a similar indication across age groups, albeit with varying evidence of efficacy; others have entirely different disease indications in adults and children; and still others are indicated for use in children only. These factors deter industry from generating evidence on the safety and efficacy of novel therapies in children, and by corollary, the submission of cost-effectiveness evidence of such therapies for pediatric health technology assessment review.

Canada lags behind the United States and Europe in regulatory provisions related to pediatric drug development. These jurisdictions have legislated both carrot-and-stick mechanisms...
to induce drug companies to study and market pediatric indica-
tions for their drugs.9 These mechanisms involve, on the one
hand, governmental perogative to mandate pediatric studies,
and, on the other, the extension of market exclusivity in
exchange for the conduct of such studies. The lack of compara-
ble provisions in Canada has abetted a sizable gap in the submis-
sion of pediatric trial data to Health Canada compared with the
US Food and Drug Administration.8

Compounding the problem posed by new drugs, most exist-
ing drugs lack approved pediatric indications, making off-label
prescribing the norm rather than the exception.10 There are no
routine mechanisms to incentivize or compel the review of drugs
already on the market for adult indications for extending public
funding recommendations to relevant pediatric indications.
Although permitted by CADTH, submissions by providers or
patient groups for either new or existing drugs are uncommon, in
large part because of the demands of such submissions, which
require the compilation and analysis of detailed clinical and
pharmacoeconomic evidence.

Finally, in an environment with limited institutional and
financial resources, setting priorities on which drugs undergo
health technology assessment review determines which drugs
get publicly funded. Again, such processes often disadvantage
children: some of the most prevalent principles employed to pri-
oritize therapies for review — including disease burden, eco-


Methodologic limitations
There are conceptual challenges to applying health technology
assessment to child health that are distinct from the system-level
challenges to child-focussed drug reviews. The adjudication of
drugs and other health technologies for public coverage in Canada
and abroad is premised on three major domains: evidence of safety
and clinical effectiveness, value for money and ethics. The relative
weight afforded the items within each domain, and the manner in
which they are integrated, vary across jurisdictions; however, the
overall parameters of assessment are similar.12 In most instances,
the normative assumptions present in these domains introduce
bias against positive funding recommendations for children.

Evidence-based medicine ranks methods of inquiry by their
susceptibility to bias; systematic reviews and meta-analyses of
data from randomized clinical trials (RCTs) are considered the
most important.13 There is strong epistemological justification
for this approach in most adult disease, but it is not useful for
pediatrics. Clinical trials in children are constrained by small
populations, and further reduced in the age of genomic classifi-
cation of disease nosology, the complexities of trial enrolment of
children and weak industry interest in pediatric drug develop-
ment.14,15 Although the child health community has worked hard
to overcome these barriers through collaborative research agen-
cas, destigmatization of pediatric research and advocacy in sup-
port of legislative reforms to regulatory environments for drug
development,16 health technology assessment reviews of drugs
for pediatric indications are often non-starters owing to a lack of
acceptable high-quality evidence.

| Table 1: Provincial and territorial drug programs that provide benefits to children* |
|-----------------------------------------------|
| **Program type**                             | NL  | PE  | NS  | NB  | QC  | ON  | MB  | AB  | BC  | YK  | NWT | NU  |
| Universal program for all residents without private insurance (deductibles are not income-indexed) | √   | √   | √†  | √   | √†  | √†  | √   |     |     |     |     |     |
| Income-indexed drug plan | √   |     |     |     |     |     |     |     |     |     |     |     |
| Income-indexed catastrophic drug plan for persons with very high costs relative to income or transitional plan for persons leaving social assistance | √   | √   | √†  | √   | √   | √   | √   |     |     |     |     |     |
| Social assistance/welfare | √   | √   | √   | √   | √   | √   | √   |     |     |     |     |     |
| Special family/child program for low-income families | √   | √   |     |     |     |     |     |     |     |     |     |     |
| Specific program for: |     |     |     |     |     |     |     |     |     |     |     |     |
| Cystic fibrosis | √   | √   |     |     |     |     |     |     |     |     |     |     |
| Diabetes | √   |     |     |     |     |     |     |     |     |     |     |     |
| Human growth hormone | √   | √   |     |     |     |     |     |     |     |     |     |     |
| Children with severe disabilities | √   | √   |     |     |     |     |     |     |     |     |     |     |
| Umbrella program for chronic disease | √   | √   | √   |     |     |     |     |     |     |     |     |     |

Note: AB = Alberta, BC = British Columbia, MB = Manitoba, NB = New Brunswick, NL = Newfoundland, NS = Nova Scotia, NU = Nunavut, NWT = Northwest Territories, ON = Ontario, PE = Prince Edward Island, QC = Quebec, SK = Saskatchewan, YK = Yukon.

*Programs described are those in effect as of April 2015 except where indicated.
†The Ontario universal pharmacare program is for all residents under 25 years of age, regardless of insurance status; effective January 2018.
‡For children who are registered Indigenous or Inuit, or infants of parents that meet these criteria.
§Alberta’s transitional program is not income-indexed and does not require cost sharing.
Standard methods for economic evaluation in health technology assessment also do not capture distinguishing features of child health and illness. Principal among these is a lack of sensitivity to life-course dynamics. Lack of data prohibits incorporation of recommended outcome metrics, such as quality-adjusted life years (QALYs), into models that assess the aggregate benefits and burdens of a given treatment over a lifetime. This is shown in the current proliferation of novel biologic and immunomodulatory therapies: there is little knowledge of the developmental and late effects of many new drugs that are brought to market, which complicates efforts to accurately assign long-term benefits and costs associated with their use in children. In addition, there are few child-specific, preference-based measures of quality of life, which compromises the calculation of QALYs for use in cost–utility analyses that form the backbone of health technology assessment.

The instruments developed to elicit health-state utilities in children often rely on parental proxies for young children. There is also almost no systematic incorporation — either in theory or in practice — of the economic impacts of a child’s illness and treatment on the family. Dependency is a critical component of virtually all childhood experience of illness that is almost never captured in pharmacoeconomic models. The current Guidelines for the Economic Evaluation of Health Technologies from CADTH do not acknowledge these issues. The absence of data is viewed as a form of uncertainty to be handled through probabilistic analysis or consultation with experts.

Ethical dilemmas are bound up in these approaches to evidence generation and economic modelling. The value of a year at any given point along a life path is commonly assumed to be constant: a QALY gained at age 2 years is routinely deemed equivalent to a QALY gained at 72 years of age. The moral legitimacy of this calculus may differ across societies. Indeed, many societies may value health gains in children more highly than in adults for many reasons: the social and economic costs of squandered potential; a belief in “fair innings,” or the value of comparable opportunities to experience life; and the intrinsic value placed on childhood itself. Social values may also dictate a preference to allocate scarce resources to those who are more vulnerable. Children are vulnerable in multiple ways: they may incur intergenerational socioeconomic disparity, they cannot advocate for themselves, and they are usually sociopolitically disenfranchised. These dynamics have equity implications for the systems constructed to conduct such drug appraisals. These systems must include the unique social values that are involved in drug appraisal and funding for children.

### Potential solutions

Developing a cohesive national framework to guide policy-making on access to drugs for children is critical for addressing the shortcomings described previously. This would strengthen the

![Figure 1: Drug approval and funding process in Canada (except in Quebec). Note: CADTH = Canadian Agency for Drugs and Technologies in Health, CDEC = Canadian Drug Expert Committee, CDR = common drug review, DIN = drug identification number, HTA = health technology assessment, NCE = new chemical entity, NOC = notice of compliance — approval of drug safety and efficacy, pCODR = pan-Canadian Oncology Drug Review, pERC = pCODR Expert Review Committee.](image-url)
technical and moral bases of decisions on drug funding and would help rationalize these decisions across provinces, thereby providing more unified and equitable access to new and existing drugs for children.

This framework should consider determinants of access from product development through to funding. Two components are integral: reform of the drug regulatory system in favour of pediatric drug research and development, and federal stewardship and pan-provincial application of standards of drug funding for children. Federal legislation to incentivize and compel industry to conduct more pediatric drug research would help attenuate gaps in evidence on drug safety and efficacy in children. It could help set priorities for pediatric drug research, spur the development of databases from clinical trials to improve transparency and reduce redundancy, and enhance regulatory harmonization across jurisdictions. Federal support for efforts to develop a national network for pediatric clinical trials in Canada would help advance the evidence base for domestic health technology assessment reviews.29

There is also an opportunity for a strengthened federal role in supporting existing cross-provincial efforts to rationalize drug purchasing through the pan-Canadian Pharmaceutical Alliance.7 Establishment of the alliance has augmented provincial coordination in the uptake of recommendations on national health technology assessment and follow-on price negotiations with industry. These laudable provincial efforts proceed from national-level recommendations on drug funding. Therefore, the right fit of principles and methods for pediatric health technology assessment is essential to ensuring that pediatric drugs are covered and at prices calibrated to their value.

Expanding the CADTH guidelines to include the conduct of health technology assessment in children would establish a universal benchmark for the conduct and adjudication of national and provincial drug reviews for pediatric indications. The use of such guidelines could be strengthened by mandating that all national-level reviews incorporate an explicit assessment of the clinical evidence, and social and economic impacts of the funding recommendation related to children. National legislation could both require and empower national health technology assessment bodies to commission industry submissions on drugs for pediatric indications, and compel or incentivize them to submit them.

The success of these efforts will depend on careful incorporation of evidentiary, economic and ethical principles that are geared to the realities of child health. As with uncommon diseases, creative approaches to trial design and evidence appraisal — including adaptive designs and access with concurrent evidence development — are needed.30 Health Canada has an important role to play as a steward of the system for pediatric drugs. It will need to work with industry and academia to facilitate innovative pediatric trials in Canada, augment market authorization for pediatric indications and equip health technology assessment bodies with the authority and resources to track postmarket use to revise appraisals in line with real-world evidence. Canadian health technology assessment bodies will need to adapt health economic models to encompass familial, developmental and life-course impacts. Because ideal models will be tempered by on-the-ground realities of data availability and system pressures, methods to ensure the incorporation of perspectives of those involved in or impacted by childhood illness should be strengthened. Many health technology assessment institutions already give voice to patient values and experiences in their drug assessments; such endeavours could be strengthened through the routine use of public engagement, such as citizen panels.31 Health technology assessment institutions could also prioritize the incorporation of pediatric-specific clinical expertise in their clinical and economic reviews.

Conclusion

Regulatory and health technology assessment systems in Canada give little regard to the unique features of child health. This has abetted an ad hoc approach to public funding decisions for pediatric drugs. Canada must create an integrated public policy framework on decision-making for drug regulation for children that is adequately funded. This will require the development and application of a coherent set of standards for appraising child health technologies, national stewardship to facilitate partnerships among key stakeholders and provincial coordination in the adoption of pan-Canadian funding recommendations.

References

1. Finney E. Children’s medicines: a situational analysis. Geneva: World Health Organization; 2011. Available: www.who.int/childmedicines/progress/CM_analysis.pdf?ua=1 (accessed 2017 June 2).

2. What is health technology assessment (HTA)? [main page]. Edmonton: International Network of Agencies for Health Technology Assessment (INAHTA). Available: www.inahsta.org/ (accessed 2017 Mar. 10).

3. Ungar WJ, Prosser LA, Burnett HF. Values and evidence colliding: health technology assessment in child health. Expert Rev Pharmacoecon Outcomes Res 2013;13:417-9.

4. Costa V, Ungar WJ. Health technology assessment in child health. In: Ungar WJ, editor. Economic Evaluation in Child Health. Oxford (UK): Oxford University Press; 2009.

5. Primary health care services for children and youth in Canada: access, quality and structure. Section 5: other primary health care services. Ottawa: Canadian Institute of Child Health; 2015. Available: http://profile.cich.ca/en/index.php/chapter3/section-5-other-primary-care-services/406 (accessed 2017 June 26).

6. Programs and services. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available: https://www.cadth.ca/about-cadth/what-we-do/products-services (accessed 2017 Mar. 20).

7. The pan-Canadian Pharmaceutical Alliance. Ottawa: Council of the Federation; 2016. Available: www.pmpovincenterritoires.ca/en/initiatives/358-pan-canadian-pharmaceutical-alliance (accessed 2017 June 1).

8. Improving medicines for children in Canada: The Expert Panel on Therapeutic Products for Infants, Children, and Youth. Ottawa: Council of Canadian Academies; 2014. Available: www.scienceadvice.gc.ca/eng/assessments%20and%20publications%20and%20news%20releases/therapeutics/therapeutics_fullreporten.pdf (accessed 2017 Mar. 10).

9. Rieder MJ; Canadian Paediatric Society, Drug Therapy and Hazardous Substances Committee. Drug research and treatment for children in Canada: a challenge. Paediatr Child Health 2011;16:560-1.

10. Palmaro A, Bissuel R, Renaud N, et al. Off-label prescribing in pediatric outpatients. Pediatrics 2015;135:49-58.

11. Noorani HZ, Huseureau DR, Boudreau R, et al. Priority setting for health technology assessments: a systematic review of current practical approaches. Int J Technol Assess Health Care 2007;23:310-5.

12. Staffinski T, Menon D, Philipp D, et al. Health technology funding decision-making processes around the world: the same, yet different. Pharmacoeconomics 2011;29:475-95.
13. Ashcroft RE. Current epistemological problems in evidence-based medicine. J Med Ethics 2004;30:131-5.

14. Kodish E, editor. Ethics and research with children: a case-based approach. New York: Oxford University Press; 2005.

15. Milne CP, Bruss JB. The economics of pediatric formulation development for off-patent drugs. Clin Ther 2008;30:2133-45.

16. Hoppu K, Anabwani G, Garcia-Bournissen F, et al. The status of paediatric medicines initiatives around the world — What has happened and what has not? Eur J Clin Pharmacol 2012;68:1-10.

17. Ungar WJ, Gerber A. The uniqueness of child health and challenges to measuring costs and consequences. In: Ungar WJ, editor. Economic evaluation in child health. Oxford (UK): Oxford University Press; 2010:3-32.

18. Keren R, Pati S, Feudtner C. The generation gap: differences between children and adults pertinent to economic evaluations of health interventions. Pharmacoeconomics 2004;22:71-81.

19. Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: Are QALYS contraindicated? Pharmacoeconomics 2011;29:641-52.

20. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2017. Available: https://www.cadth.ca/about-cadth/how-we-do-it/methods-and-guidelines/guidelines-for-the-economic-evaluation-of-health-technologies-canada (accessed 2017 Mar. 30).

21. Weinstein MC. A QALY is a QALY is a QALY — Or is it? J Health Econ 1988;7:289-90.

22. Brock DW, Daniels N, Neumann PJ, et al. Ethical and distributive considerations. In: Neumann PJ, Ganiats TG, Russell LB, et al., editors. Cost-effectiveness in health and medicine. 2nd ed. Oxford (UK): Oxford University Press; 2016:319-42.

23. Donaldson C, Baker R, Mason H, et al. The social value of a QALY: Raising the bar or barring the raise? BMC Health Serv Res 2011;11:8.

24. Nord E, Street A, Richardson J, et al. The significance of age and duration of effect in social evaluation of health care. Health Care Anal 1996;4:103-11.

25. Gormley W. Voices for children: rhetoric and public policy. Washington: Brookings Institution Press; 2012.

26. Williams A. Intergenerational equity: an exploration of the ‘fair innings’ argument. Health Econ 1997;6:117-32.

27. Mayall B. Values and assumptions underpinning policy for children and young people in England. Child Geogr 2006;4:9-17.

28. Petrou S. Should health gains by children be given the same value as health gains by adults in an economic evaluation framework? In: Ungar WJ, editor. Economic evaluation in child health. Oxford (UK): Oxford University Press; 2010:71-87.

29. Best practices for health research involving children and adolescents: genetic, pharmaceutical and longitudinal studies. Montréal: Centre of Genomics and Policy; and Vancouver: Maternal Infant Child and Youth Research Network; 2012.

30. Abrahamyan L, Feldman BM, Tomlinson G, et al. Alternative designs for clinical trials in rare diseases. Am J Med Genet C Semin Med Genet 2016;172:313-31.

31. Abelson J, Giacomini M, Lehoux P, et al. Bringing the ‘public’ into health technology assessment and coverage policy decisions: From principles to practice. Health Policy 2007;82:37-50.